The eye is a very valuable organ that can be affected by many diseases. These eye diseases can affect the body and the person may also lose their vision. Hence, there are many drug delivery systems available in the market to treat these eye diseases. As a result of efficient protective mechanisms of the eye, there are a few ophthalmic drugs available in the market. Almost 70% of the eye dosage formulations available in the market are in the form of eye drops and ointments. But since these drops and ointments are drained away from the ocular cavity owing to tear flow and lachrymal nasal drainage, novel and advanced pharmaceutical ophthalmic formulations are emerging in the market. These formulations are available in the form of in-situ gel, microemulsion, nanoparticle, liposome, iontophoresis, nanosuspension, and ocular inserts.
The major factors that drive the growth of the global ocular drug delivery technology market are the low bioavailability of drugs in conventional ocular therapies, increase in the incidence of glaucoma & macular degeneration, growing demand for targeted ocular drug delivery techniques, and increase in the number of approvals from government regulations for new ocular drug delivery techniques. Favorable reimbursement policies and rise in funding to develop advanced drug delivery systems can help boost the market growth. However, the solidity of the implants can lead to discomfort accompanied by drug dilution, irritation, and excessive lachrymation, which can restrain the market growth.
The global ocular drug delivery market is segmented based on technology, formulation type, disease type, end user, and geography. Based on technology, the market is categorized into topical, iontophoresis, ocular insert, intraocular implants, in situ gel & punctal plugs, and others. Ocular insert is further bifurcated into erodible and non-erodible. Intraocular implants are further divided into biodegradable and non-biodegradable. Based on formulation type, the market is categorized into liposomes & nanoparticles, solution, emulsion, suspension, and ointment. Based on disease type, the market is further segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. Based on end-users, the market is further classified into hospitals, ophthalmic clinics, ambulatory surgical centers, and homecare settings. Based on geography, the market has been examined across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, EyeGate Pharma, Envisia Therapeutics, and Allergan, Plc. have also been provided in this report.
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
- This report entails a detailed quantitative analysis of the current market and estimations from 2017-2023, which assists in identifying prevailing market opportunities.
- The projections in this report are made by analyzing the current trends and future market potential from 2017 to 2023 in terms of value.
- Competitive intelligence helps understand the competitive scenario globally
- An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.
Ocular Drug Delivery Market Key Segments:
- Ocular Insert
- Intraocular Implants
- In Situ Gel & Punctal Plugs
By Formulation Type
- Liposomes & Nanoparticles
By Disease Type
- Diabetic Retinopathy
- Dry Eye Syndrome
- Macular Degeneration
- Diabetic Macular Edema
By End Users
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."